Alexandra Hudson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexandra Hudson has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Kim Blake
Dalhousie University Faculty of Medicine, Halifax, Nova Scotia, Canada
8 shared publications - Eytan Wine
University of Alberta
4 shared publications - Hien Quoc Huynh
Edmonton Pediatric IBD Clinic (EPIC), Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, University of Alberta , Edmonton, Alberta
4 shared publications Dale Lee
Division of Pediatric Gastroenterology Seattle Children's Hospital, Inflammatory Bowel Disease Center University of Washington Seattle Washington USA
3 shared publicationsGhassan Wahbeh
Division of Pediatric Gastroenterology Seattle Children's Hospital, Inflammatory Bowel Disease Center University of Washington Seattle Washington USA
3 shared publicationsKim Blake
Department of Pediatrics, IWK Health Centre, Halifax, Nova Scotia, Canada
3 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
Electronic consultation and referral service is safe and reduces the need for tertiary evaluations for disorders of gut–brain interaction in children
Background: Electronic consultation systems are increasingly used to improve access to specialists due to growing demand and prolonged wait times. Our Pediatric Gastroenterology Division in Edmonton launched an eReferral system in 2020, which allows healthcare providers to seek patient-related advice and directly refer to our subspecialty. Methods: As a quality improvement project, we completed a retrospective chart review of paediatric gastroenterology eReferrals in Edmonton from 2022 to 2023. We aimed to understand patient outcomes, including emergency department visits, hospitalizations, and need for formal gastroenterology consultation and/or endoscopy. Results: A total of 318 patients were referred through eReferral during the 2-year period. Most patients (263/318, 83%) were initially referred conventionally, via fax, or electronic medical record referral module, and were redirected by the triaging physician to seek eReferral advice. The remainder were self-initiated eReferral requests. In total, 11% (34/318) of eReferral patients visited the emergency department for the same gastroenterology concern after eReferral advice. Only 76/318(24%) of eReferral patients were seen by paediatric gastroenterology. About 26/76(34%) of these patients underwent endoscopy, and the majority of findings (21/26, 81%) were normal or non-specific without relevance to the patient’s symptoms or management. About 43/76(57%) of patients reviewed by gastroenterology were ultimately diagnosed with a disorder of gut–brain interaction (DGBI). Conclusions: The eReferral system appears to be an effective tool in the management and care of paediatric patients with suspected DGBIs referred to our paediatric gastroenterology service. Most of these patients have disorders that do not require endoscopy or formal GI consultation. Timely e-advice to referring physicians can expedite enhanced care in the patient’s medical home.
- 17 August 2026
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
Open AccessElectronic consultation and referral service is safe and reduces the need for tertiary evaluations for disorders of gut–brain interaction in children
Background: Electronic consultation systems are increasingly used to improve access to specialists due to growing demand and prolonged wait times. Our Pediatric Gastroenterology Division in Edmonton launched an eReferral system in 2020, which allows healthcare providers to seek patient-related advice and directly refer to our subspecialty. Methods: As a quality improvement project, we completed a retrospective chart review of paediatric gastroenterology eReferrals in Edmonton from 2022 to 2023. We aimed to understand patient outcomes, including emergency department visits, hospitalizations, and need for formal gastroenterology consultation and/or endoscopy. Results: A total of 318 patients were referred through eReferral during the 2-year period. Most patients (263/318, 83%) were initially referred conventionally, via fax, or electronic medical record referral module, and were redirected by the triaging physician to seek eReferral advice. The remainder were self-initiated eReferral requests. In total, 11% (34/318) of eReferral patients visited the emergency department for the same gastroenterology concern after eReferral advice. Only 76/318(24%) of eReferral patients were seen by paediatric gastroenterology. About 26/76(34%) of these patients underwent endoscopy, and the majority of findings (21/26, 81%) were normal or non-specific without relevance to the patient’s symptoms or management. About 43/76(57%) of patients reviewed by gastroenterology were ultimately diagnosed with a disorder of gut–brain interaction (DGBI). Conclusions: The eReferral system appears to be an effective tool in the management and care of paediatric patients with suspected DGBIs referred to our paediatric gastroenterology service. Most of these patients have disorders that do not require endoscopy or formal GI consultation. Timely e-advice to referring physicians can expedite enhanced care in the patient’s medical home.
- Open Access
- 10 March 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (3)
Early intestinal ultrasound findings predict remission and treatment response at 1 year in pediatric Crohn’s disease
Intestinal ultrasound (IUS) in pediatric IBD is increasing, but evidence remains limited compared with adults. This study aimed to evaluate the relationship between IUS and clinical, biochemical, and endoscopic measures in pediatric Crohn’s disease patients over 1 year, and to assess its ability to predict treatment response and remission. Pediatric patients with suspected inflammatory bowel disease were prospectively enrolled and assessed over 1 year. Bowel wall thickness (BWT) and three validated IUS scores were calculated. Remission was combined clinical/biochemical/endoscopic remission. Treatment response was not needing therapy escalation and achieving remission by 1 year. Sixty-one patients, median age 12.3 years (IQR 10.3-14.7; range 6-17), were included. IUS correlated moderately to strongly with endoscopy (rho 0.43-0.70). Thicker terminal ileum BWT was associated with increased likelihood of ileocecal resection (n = 7, 12%) (OR = 5.85, 95% CI 1.29-26.47, P < .05). Patients’ thickest bowel segment became significantly thinner at 1 month (P < .05). Thicker BWT at 6 months was associated with a decreased likelihood of 1-year remission (OR = 0.34; 95% CI 0.16-0.74, P = .006). BWT ≤ 2.8 mm at 6 months predicted treatment response with high sensitivity (73%) and specificity (84%). BWT ≤ 2.5 mm at 1 year predicted remission with high sensitivity (72%) and specificity (90%). IUS correlated strongly with endoscopy in pediatric Crohn’s disease over 1 year, with increased BWT being associated with a higher risk of ileocecal resection and not achieving remission. Thickened (inflamed) bowel became significantly thinner as soon as 1 month. BWT in pediatric patients in remission was significantly lower (≤2.5 mm) than in adults (≤3–4 mm).
- 10 March 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (3)
Open AccessEarly intestinal ultrasound findings predict remission and treatment response at 1 year in pediatric Crohn’s disease
Intestinal ultrasound (IUS) in pediatric IBD is increasing, but evidence remains limited compared with adults. This study aimed to evaluate the relationship between IUS and clinical, biochemical, and endoscopic measures in pediatric Crohn’s disease patients over 1 year, and to assess its ability to predict treatment response and remission. Pediatric patients with suspected inflammatory bowel disease were prospectively enrolled and assessed over 1 year. Bowel wall thickness (BWT) and three validated IUS scores were calculated. Remission was combined clinical/biochemical/endoscopic remission. Treatment response was not needing therapy escalation and achieving remission by 1 year. Sixty-one patients, median age 12.3 years (IQR 10.3-14.7; range 6-17), were included. IUS correlated moderately to strongly with endoscopy (rho 0.43-0.70). Thicker terminal ileum BWT was associated with increased likelihood of ileocecal resection (n = 7, 12%) (OR = 5.85, 95% CI 1.29-26.47, P < .05). Patients’ thickest bowel segment became significantly thinner at 1 month (P < .05). Thicker BWT at 6 months was associated with a decreased likelihood of 1-year remission (OR = 0.34; 95% CI 0.16-0.74, P = .006). BWT ≤ 2.8 mm at 6 months predicted treatment response with high sensitivity (73%) and specificity (84%). BWT ≤ 2.5 mm at 1 year predicted remission with high sensitivity (72%) and specificity (90%). IUS correlated strongly with endoscopy in pediatric Crohn’s disease over 1 year, with increased BWT being associated with a higher risk of ileocecal resection and not achieving remission. Thickened (inflamed) bowel became significantly thinner as soon as 1 month. BWT in pediatric patients in remission was significantly lower (≤2.5 mm) than in adults (≤3–4 mm).
- Open Access
- 12 November 2025
- Published by Wiley in JPGN Reports
- Vol. 7 (1) , 99-106
Impact of timing on mucosal healing during restaging endoscopy in pediatric Crohn's disease: A retrospective cohort study
While endoscopic remission is an important target in pediatric Crohn's disease (CD), no consensus for restaging timing exists. This retrospective cohort study assessed the timing and impact of restaging endoscopy in children with new CD in remission, comparing earlier ( ≤ 9 months) versus later endoscopy. Twenty‐five patients were included (median: 12.6 years, range: 5–17). Endoscopic remission (no ulcerations) was achieved in 72% ( n = 18/25). Thirteen patients (52%) had earlier endoscopy (median: 7 months, interquartile range [IQR]: 6–9, range: 3–9) while 12 (48%) had later (median: 14.5 months, IQR: 13–17, range: 11–20). There were no differences in endoscopic remission (earlier 77% vs. later 67%; p = 0.69) or therapy escalation after restaging (earlier 23% vs. later 42%; p = 0.44). This study demonstrates that one in four pediatric Crohn's disease patients in clinical and biochemical remission were not in endoscopic remission, regardless of the timing of restaging endoscopy. This indicates potential benefit to earlier restaging endoscopy in clinical decision‐making.
- 12 November 2025
- Published by Wiley in JPGN Reports
- Vol. 7 (1) , 99-106
Open AccessImpact of timing on mucosal healing during restaging endoscopy in pediatric Crohn's disease: A retrospective cohort study
While endoscopic remission is an important target in pediatric Crohn's disease (CD), no consensus for restaging timing exists. This retrospective cohort study assessed the timing and impact of restaging endoscopy in children with new CD in remission, comparing earlier ( ≤ 9 months) versus later endoscopy. Twenty‐five patients were included (median: 12.6 years, range: 5–17). Endoscopic remission (no ulcerations) was achieved in 72% ( n = 18/25). Thirteen patients (52%) had earlier endoscopy (median: 7 months, interquartile range [IQR]: 6–9, range: 3–9) while 12 (48%) had later (median: 14.5 months, IQR: 13–17, range: 11–20). There were no differences in endoscopic remission (earlier 77% vs. later 67%; p = 0.69) or therapy escalation after restaging (earlier 23% vs. later 42%; p = 0.44). This study demonstrates that one in four pediatric Crohn's disease patients in clinical and biochemical remission were not in endoscopic remission, regardless of the timing of restaging endoscopy. This indicates potential benefit to earlier restaging endoscopy in clinical decision‐making.
- 13 October 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (2) , 419-425
Prevalence of Dysautonomic Symptoms in CHARGE Syndrome: A Pilot Study of 25 Individuals With CHARGE Syndrome
CHARGE syndrome is a heterogeneous genetic disorder with an evolving phenotype, particularly in adults. This study examined whether dysautonomic symptoms are common in adolescents and adults with CHARGE syndrome. Adolescents and adults with CHARGE syndrome completed a CHARGE‐specific checklist and modified items from COMPASS‐31 with the cardiovascular items from the ASP to assess dysautonomic symptoms. Participants were 25 individuals (20 female, 5 male), aged 12–33 years (mean = 21.3 years), with clinically confirmed diagnoses, 16 of whom had a CHD7 mutation. Dysautonomic symptoms were common: 50%–60% reported fatigue, heat intolerance, constipation, nausea, and headaches; 40%–50% reported postural tachycardia, tachycardia, dyspnea, weakness, exercise intolerance, and anxiety. These rates appear at a high frequency. A detailed case study of one participant is included in the supplemental material. Findings suggest dysautonomia may be prevalent in individuals with CHARGE syndrome and highlight the need for greater awareness of symptoms and triggers. Interventions such as vagal nerve stimulation may help restore autonomic balance and improve quality of life.
- 13 October 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (2) , 419-425
Prevalence of Dysautonomic Symptoms in CHARGE Syndrome: A Pilot Study of 25 Individuals With CHARGE Syndrome
CHARGE syndrome is a heterogeneous genetic disorder with an evolving phenotype, particularly in adults. This study examined whether dysautonomic symptoms are common in adolescents and adults with CHARGE syndrome. Adolescents and adults with CHARGE syndrome completed a CHARGE‐specific checklist and modified items from COMPASS‐31 with the cardiovascular items from the ASP to assess dysautonomic symptoms. Participants were 25 individuals (20 female, 5 male), aged 12–33 years (mean = 21.3 years), with clinically confirmed diagnoses, 16 of whom had a CHD7 mutation. Dysautonomic symptoms were common: 50%–60% reported fatigue, heat intolerance, constipation, nausea, and headaches; 40%–50% reported postural tachycardia, tachycardia, dyspnea, weakness, exercise intolerance, and anxiety. These rates appear at a high frequency. A detailed case study of one participant is included in the supplemental material. Findings suggest dysautonomia may be prevalent in individuals with CHARGE syndrome and highlight the need for greater awareness of symptoms and triggers. Interventions such as vagal nerve stimulation may help restore autonomic balance and improve quality of life.
- 20 August 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (7) , 1690-1700
The Impact of Integrating Pelvic Magnetic Resonance Imaging at Diagnosis on Early Detection of Perianal Crohn's Disease in Pediatrics
INTRODUCTION: Perianal Crohn's disease (CD) can be a severe manifestation of pediatric CD. Earlier detection may alter outcomes. The aim of this study was to determine if performing pelvic magnetic resonance imaging (MRI) on newly diagnosed pediatric patients with CD would identify asymptomatic perianal CD and lead to earlier biologic use and less perianal surgery. METHODS: Patients were prospectively enrolled into the Edmonton Pediatric Inflammatory Bowel Disease Clinic registry (baseline pelvic MRI since 2018). A retrospective review (2018–2023) was performed. A blinded radiologist re-read the positive MRIs using St. James and Parks criteria. RESULTS: One hundred thirty-nine patients were included (median age 13 [interquartile range 11–16, range 6–18]). Overall, 19% (n = 27/139) had subclinical perianal disease (MR+/asymptomatic [ASx]). For patients who were both asymptomatic and had a normal perianal examination (n = 86/139, 62%), their subclinical perianal disease rate was similar at 20% (n = 17/86). Compared with MR−/ASx, MR+/ASx patients had a relative risk of 1.40 (95% confidence interval [CI] 1.18–1.68) and 1.32 (95% CI 1.17–1.52) of starting a biologic at 6 and 12 months, respectively. MR+/Sx needed the most and earliest perianal surgery, but MR+/ASx also had higher rates and faster time to perianal surgery than MR−/ASx (P = 0.02). Perianal side branch fistula was a predictor of surgery (odds ratio 107.6, [95% CI 16.9–2,178] P < 0.0001). DISCUSSION: One in 5 newly diagnosed pediatric patients with CD had subclinical perianal disease, even when having a normal perianal physical examination. These patients needed more and earlier perianal surgery and had higher biologic use despite their perianal disease being subclinical. Adding routine MR imaging at the time of pediatric CD diagnosis may help inform treatment decisions and improve these outcomes.
- 20 August 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (7) , 1690-1700
The Impact of Integrating Pelvic Magnetic Resonance Imaging at Diagnosis on Early Detection of Perianal Crohn's Disease in Pediatrics
INTRODUCTION: Perianal Crohn's disease (CD) can be a severe manifestation of pediatric CD. Earlier detection may alter outcomes. The aim of this study was to determine if performing pelvic magnetic resonance imaging (MRI) on newly diagnosed pediatric patients with CD would identify asymptomatic perianal CD and lead to earlier biologic use and less perianal surgery. METHODS: Patients were prospectively enrolled into the Edmonton Pediatric Inflammatory Bowel Disease Clinic registry (baseline pelvic MRI since 2018). A retrospective review (2018–2023) was performed. A blinded radiologist re-read the positive MRIs using St. James and Parks criteria. RESULTS: One hundred thirty-nine patients were included (median age 13 [interquartile range 11–16, range 6–18]). Overall, 19% (n = 27/139) had subclinical perianal disease (MR+/asymptomatic [ASx]). For patients who were both asymptomatic and had a normal perianal examination (n = 86/139, 62%), their subclinical perianal disease rate was similar at 20% (n = 17/86). Compared with MR−/ASx, MR+/ASx patients had a relative risk of 1.40 (95% confidence interval [CI] 1.18–1.68) and 1.32 (95% CI 1.17–1.52) of starting a biologic at 6 and 12 months, respectively. MR+/Sx needed the most and earliest perianal surgery, but MR+/ASx also had higher rates and faster time to perianal surgery than MR−/ASx (P = 0.02). Perianal side branch fistula was a predictor of surgery (odds ratio 107.6, [95% CI 16.9–2,178] P < 0.0001). DISCUSSION: One in 5 newly diagnosed pediatric patients with CD had subclinical perianal disease, even when having a normal perianal physical examination. These patients needed more and earlier perianal surgery and had higher biologic use despite their perianal disease being subclinical. Adding routine MR imaging at the time of pediatric CD diagnosis may help inform treatment decisions and improve these outcomes.
- Open Access
- 18 July 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 765-815
Management of paediatric ulcerative colitis, part 1: Ambulatory care—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation
Objectives: Despite advances in the management of ambulatory paediatric ulcerative colitis (UC), challenges remain as many patients are refractory to therapy and some require colectomy. The aim of these guidelines is to provide an update on optimal care for UC through detailed recommendations and practice points. Methods: These guidelines are an update to those published in 2018 and are a joint effort of the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation. An extensive literature search with subsequent evidence appraisal using the Oxford methodology was performed, followed by three online voting sessions and a consensus face‐to‐face meeting. Thirty‐nine recommendations and 77 practice points were endorsed by the 25 experts with at least an 84% consensus rate. Results: Robust evidence‐based recommendations and detailed practice points are provided. In addition to reemphasising and updating the role of more ‘traditional’ UC therapies, these guidelines outline optimising the use of antitumour necrosis factor therapies and integrating newer biologics and small molecules, as well as supportive therapy, to improve outcomes and provide an updated management algorithm. Measurement and monitoring tools and decision aids are provided, and additional aspects, including nutritional support, extraintestinal manifestations, pouchitis, inflammatory bowel disease‐unclassified and patient support, are discussed. Some aspects, including surgery and thromboprophylaxis, are covered in the acute severe UC guidelines. Conclusions: These guidelines serve as an aid in managing children with UC through a combination of evidence‐based recommendations and more practical practice points in the ambulatory setting.
- 18 July 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 765-815
Open AccessManagement of paediatric ulcerative colitis, part 1: Ambulatory care—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation
Objectives: Despite advances in the management of ambulatory paediatric ulcerative colitis (UC), challenges remain as many patients are refractory to therapy and some require colectomy. The aim of these guidelines is to provide an update on optimal care for UC through detailed recommendations and practice points. Methods: These guidelines are an update to those published in 2018 and are a joint effort of the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation. An extensive literature search with subsequent evidence appraisal using the Oxford methodology was performed, followed by three online voting sessions and a consensus face‐to‐face meeting. Thirty‐nine recommendations and 77 practice points were endorsed by the 25 experts with at least an 84% consensus rate. Results: Robust evidence‐based recommendations and detailed practice points are provided. In addition to reemphasising and updating the role of more ‘traditional’ UC therapies, these guidelines outline optimising the use of antitumour necrosis factor therapies and integrating newer biologics and small molecules, as well as supportive therapy, to improve outcomes and provide an updated management algorithm. Measurement and monitoring tools and decision aids are provided, and additional aspects, including nutritional support, extraintestinal manifestations, pouchitis, inflammatory bowel disease‐unclassified and patient support, are discussed. Some aspects, including surgery and thromboprophylaxis, are covered in the acute severe UC guidelines. Conclusions: These guidelines serve as an aid in managing children with UC through a combination of evidence‐based recommendations and more practical practice points in the ambulatory setting.
- 17 June 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 816-851
Management of paediatric ulcerative colitis, part 2: Acute severe colitis—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization
Acute severe colitis (ASC) is a relatively frequent manifestation in children with ulcerative colitis and one of the few emergencies in paediatric gastroenterology. A standardized proactive approach based on tight monitoring and timely medical and surgical interventions may improve patients' outcomes. We aimed to update the previous ASC guidelines using detailed recommendations and practice points, based on a systematic review of the literature and consensus of experts. These guidelines update is a joint effort of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization. A systematic search was performed in Pubmed Ovid Medline, Embase and Cochrane databases using 13 predefined PICO (patient, intervention, comparison, outcomes) based questions and 30 non‐PICO based questions. Grading methodology was based on the Oxford Centre for Evidence‐Based Medicine—Levels of evidence. The questions were addressed by working subgroups following an iterative consensus voting process, including three online voting meetings and one face‐to‐face meeting. A total of 36 recommendations and 72 practice points were endorsed with a consensus rate of at least 88% for all statements, regarding initial evaluation, monitoring, medical and surgical treatment of ASC in children. Several topics have been revised since the previous 2018 guidelines and differ from corresponding published adult guidelines. These guidelines present a comprehensive overview of the management of ASC in children, offering practical recommendations and practice points aiming to standardize clinical and surgical treatment and improve outcomes of this severe scenario.
- 17 June 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 816-851
Management of paediatric ulcerative colitis, part 2: Acute severe colitis—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization
Acute severe colitis (ASC) is a relatively frequent manifestation in children with ulcerative colitis and one of the few emergencies in paediatric gastroenterology. A standardized proactive approach based on tight monitoring and timely medical and surgical interventions may improve patients' outcomes. We aimed to update the previous ASC guidelines using detailed recommendations and practice points, based on a systematic review of the literature and consensus of experts. These guidelines update is a joint effort of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization. A systematic search was performed in Pubmed Ovid Medline, Embase and Cochrane databases using 13 predefined PICO (patient, intervention, comparison, outcomes) based questions and 30 non‐PICO based questions. Grading methodology was based on the Oxford Centre for Evidence‐Based Medicine—Levels of evidence. The questions were addressed by working subgroups following an iterative consensus voting process, including three online voting meetings and one face‐to‐face meeting. A total of 36 recommendations and 72 practice points were endorsed with a consensus rate of at least 88% for all statements, regarding initial evaluation, monitoring, medical and surgical treatment of ASC in children. Several topics have been revised since the previous 2018 guidelines and differ from corresponding published adult guidelines. These guidelines present a comprehensive overview of the management of ASC in children, offering practical recommendations and practice points aiming to standardize clinical and surgical treatment and improve outcomes of this severe scenario.
- 15 February 2025
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 21 (2) , 199-207
Concurrent pediatric eosinophilic esophagitis and inflammatory bowel disease: a longitudinal single center case‒control study and literature review
- 15 February 2025
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 21 (2) , 199-207
Concurrent pediatric eosinophilic esophagitis and inflammatory bowel disease: a longitudinal single center case‒control study and literature review
- Open Access
- 6 February 2025
- Published by Wiley in JPGN Reports
- Vol. 6 (2) , 132-136
Self‐assessment with pediatric inflammatory bowel disease endoscopy scoring tools: A quality improvement pilot study
Endoscopy is a fundamental component pediatric gastroenterology (GI), with one of its primary applications being the evaluation and management of patients with inflammatory bowel disease (IBD). However, there is variation in education and experience of gastroenterologists with pediatric IBD endoscopy, which can affect the quality of patient care. This quality improvement pilot study assessed familiarity and comfort with key endoscopic assessment tools (13 questions) pre‐ and post‐ an evidence‐based group presentation. Both fellow and attending pediatric gastroenterologists had low levels of comfort with endoscopic Crohn's disease scoring, IBD phenotype classification, postoperative IBD scoring, and IBD dysplasia screening. The review presentation significantly enhanced their comfort, with this effect persisting for several months among fellows. To improve the quality of care for IBD patients, it would be beneficial to periodically review endoscopic guidelines in continuing medical education for pediatric gastroenterologists providing IBD care.
- 6 February 2025
- Published by Wiley in JPGN Reports
- Vol. 6 (2) , 132-136
Open AccessSelf‐assessment with pediatric inflammatory bowel disease endoscopy scoring tools: A quality improvement pilot study
Endoscopy is a fundamental component pediatric gastroenterology (GI), with one of its primary applications being the evaluation and management of patients with inflammatory bowel disease (IBD). However, there is variation in education and experience of gastroenterologists with pediatric IBD endoscopy, which can affect the quality of patient care. This quality improvement pilot study assessed familiarity and comfort with key endoscopic assessment tools (13 questions) pre‐ and post‐ an evidence‐based group presentation. Both fellow and attending pediatric gastroenterologists had low levels of comfort with endoscopic Crohn's disease scoring, IBD phenotype classification, postoperative IBD scoring, and IBD dysplasia screening. The review presentation significantly enhanced their comfort, with this effect persisting for several months among fellows. To improve the quality of care for IBD patients, it would be beneficial to periodically review endoscopic guidelines in continuing medical education for pediatric gastroenterologists providing IBD care.